Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is increasingly used in the treatment of
chronic lymphocytic leukemia (CLL). Moreover, very promising results have been reported in …

Background Lymphoid neoplasms treatment has recently been renewed to increase
antitumor efficacy and conventional chemotherapies toxicities. Limited data have been …

Disseminated disease following invasive pulmonary aspergillosis (IPA) remains a significant
contributor to mortality amongst patients with hematologic malignancies (HMs). At the …

Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and
previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved …

(CLL) in remission taking acalabrutinib was admitted for acute kidney injury, confusion, and
1-month history of progressive left ocular symptoms. The patient was hemodynamically …

Ibrutinib has revolutionized the treatment of chronic lymphoid malignancies. Despite its
success, ibrutinib has been linked with several reports of invasive fungal infections. We …

Ubiquitous in nature, Aspergillus rarely invades the brain to induce infection in general.
However, in clinical practice, some patients with hematological malignancies or …

Innovative therapeutic strategies, applied in first line, have contributed to improved
outcomes in patients with PCNSL, making this disease potentially curable in young and fit …

Abstract Background Aspergillosis of Central Nervous System (CNS) is a highly lethal
infection in patients with leukemia and Stem Cell Transplantation (SCT). Methods Case …